Shengwu Liu
Broad Institute(US)Brigham and Women's Hospital(US)Harvard University(US)Dana-Farber Cancer Institute(US)
Publications by Year
Research Areas
Lung Cancer Treatments and Mutations, Histone Deacetylase Inhibitors Research, Protein Degradation and Inhibitors, Peptidase Inhibition and Analysis, PI3K/AKT/mTOR signaling in cancer
Most-Cited Works
- → Mechanisms and clinical activity of an EGFR and HER2 exon 20–selective kinase inhibitor in non–small cell lung cancer(2018)447 cited
- → Prostate cancer–associated SPOP mutations confer resistance to BET inhibitors through stabilization of BRD4(2017)333 cited
- → T-cell Immunoglobulin and ITIM Domain (TIGIT) Receptor/Poliovirus Receptor (PVR) Ligand Engagement Suppresses Interferon-γ Production of Natural Killer Cells via β-Arrestin 2-mediated Negative Signaling(2014)248 cited
- → Mobocertinib (TAK-788): A Targeted Inhibitor of EGFR Exon 20 Insertion Mutants in Non–Small Cell Lung Cancer(2021)190 cited
- → Synergistic Immunostimulatory Effects and Therapeutic Benefit of Combined Histone Deacetylase and Bromodomain Inhibition in Non–Small Cell Lung Cancer(2017)150 cited
- → Targeting HER2 Aberrations in Non–Small Cell Lung Cancer with Osimertinib